What the FDA labels say about taking them together
Methotrexate and penicillamine
Methotrexate's FDA label (Rasuvo) of December 15, 2025 names penicillamine in its drug interactions section; the penicillamine labels PlainMeds reads (2) do not name methotrexate. The methotrexate label: “Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects.”
Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the penicillamine FDA label on DailyMed (effective January 26, 2026, Bausch Health US, LLC).
What does the methotrexate label say about penicillamine?
Rasuvo label (Medexus Pharma Inc., December 15, 2025), drug interactionsCombined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects.
Source: FDA drug label (Rasuvo, NDA205776), Medexus Pharma Inc., effective December 15, 2025 (SPL set d0075461-0e7e-4967-9c9b-d6440e912c0e), via openFDA
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
What does the penicillamine label say about methotrexate?
Penicillamine's label (effective January 26, 2026) and its 1 other brand-application label do not name methotrexate in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cuprimine), NDA019853 (Valeant Pharms Intl), as published by Bausch Health US, LLC, effective January 26, 2026 (SPL set 80e736d3-2017-4d68-94b4-38255c3c59c6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methotrexate | Penicillamine | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancer | Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.158 per tablet 2.5 mg tablet | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once